Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

• Status: Terminated
• Trial end date: 2017-01-27
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Nivolumab

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• SCLC or PAC that is advanced or has spread to other parts of the body

• Treated with at least one other chemotherapy that did not work or where cancer relapsed

• Minimal limitations on activities of daily living as measured by Eastern Cooperative Oncology Group (ECOG) score of 0-1

Exclusion Criteria:

• Patients with cancer that spread to the brain

• Active, known or suspected autoimmune disease

• Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)